National Cancer Institute®
Last Modified: May 1, 2002
UI - 11889695
AU - Leenman EE; Tsinzerling VA; Pozharisskii KM
TI - [Morphological and immunohistochemical characteristics of primary brain lymphomas in AIDS patients]
SO - Arkh Patol 2002 Jan-Feb;64(1):25-9
AD - N.N. Petrov Cancer Research Institute, 186646, St-Petersburg.
Primary lymphomas of the brain were studied in 6 AIDS patients. The lymphomas were characterized by multicentricity, extended necroses and location in large hemispheres. Two types of tumor cell growth were recorded: diffuse and perivascular with vascular wall destruction. According to the International Histologic Classification (2001), these lymphomas were classified as diffuse B-cell large cell lymphomas subdivided into 3 variants: immunoblastic with plasma cell differentiation, centroblastic polymorphic and large cell anaplastic (by Kils classification criteria). Immunohistochemically (LMP-1) and by hybridization in situ (RNA EBER-1,2) Epstein-Barr virus was found in tumor cells from all the patients. In 5 of 6 cases studied expression of the antiapoptotic protein bcl-2 and in 2 cases expression of mutant p53 were revealed.
UI - 11884058
AU - Bhama JK; Azad NS; Fisher WE
TI - Primary anorectal lymphoma presenting as a perianal abscess in an HIV-positive male.
SO - Eur J Surg Oncol 2002 Mar;28(2):195-7
AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine and The Veteran Affairs Medical Center, Houston, Texas 77030, USA.
UI - 11699213
AU - Preciado MV; De Matteo E; Fallo A; Chabay P; Drelichman G; Grinstein S
TI - EBV-associated Hodgkin's disease in an HIV-infected child presenting with a hemophagocytic syndrome.
SO - Leuk Lymphoma 2001 Jun;42(1-2):231-4
AD - Laboratory of Virology, Ricardo Gutierrez Children Hospital, Gallo 1330, 1425 Ciudad de Buenos Aires, Argentina. firstname.lastname@example.org
An 8-years-old boy was admitted with fever of unknown origin, cervical lymphadenopathy and hepatosplenomegaly and weight loss. His mother's HIV infection was diagnosed two weeks before his hospitalization, so he was diagnosed as perinatally acquired AIDS. Serology and serial cultures were negative for viral infections, toxoplasmosis, chagas, tuberculosis and atypical mycobacterium. The patient met clinical and laboratory criteria for hemophagocytic syndrome (HS) that was confirmed on bone marrow aspirate and biopsy. A cervical lymph node biopsy was performed which was diagnosed as Hodgkin's disease (HD) diffuse fibrosis lymphocyte depletion subtype. EBERs in situ hybridization and LMP-1 immunohistochemistry on the lymph node biopsy established the EBV association. On the basis of a sequence of appearance of the clinical, laboratory and histological signs, HIV, EBV or HD may have triggered HS as the last fatal event in this pediatric patient.
UI - 11860669
AU - Vilchez RA; Kozinetz CA; Jorgensen JL; Kroll MH; Butel JS
TI - AIDS-related systemic non-Hodgkin's lymphoma at a large community program.
SO - AIDS Res Hum Retroviruses 2002 Mar 1;18(4):237-42
AD - Department of Medicine, Baylor Center for AIDS Research, Baylor College of Medicine, Houston, Texas 77030, USA. email@example.com
The introduction of triple antiretroviral therapy has led to reductions in opportunistic diseases in HIV-infected patients. However, little is known of the effect of this therapy on the clinical and pathological features and the outcome of patients with AIDS-related systemic non-Hodgkin's lymphoma (NHL). We examined the incidence and clinical manifestations of HIV-infected patients with systemic NHL at the Harris County Hospital District and Veterans Affairs Medical Center (Houston, were diagnosed in 3655 HIV-infected patients. Three groups of patients diagnosed with systemic NHL were identified according to their history of antiretroviral therapy: treatment naive (n = 20), dual nucleoside (n = 22), and triple antiretroviral drug-treated patients (n = 34). The median duration of antiretroviral therapy before the diagnosis of systemic NHL in the triple antiretroviral and dual nucleoside treatment groups was 12 versus 8 months (p < 0.0004). Thirty-five percent of patients (12 of 34) in the triple treatment group had an HIV RNA viral load of <400 copies/ml and their median CD4+ cell count was 301 cells/mm(3) (range, 46 to 667 cells/mm(3)) at the time of diagnosis of systemic NHL. More patients treated with triple antiretroviral therapy received complete courses of chemotherapy as compared with the other two groups (p = 0.013). However, the overall survival did not differ significantly among the three groups of patients. These data suggest that AIDS-related systemic NHL continues to occur even in patients treated with triple antiretroviral therapy. In addition, this opportunistic malignancy is associated with significant mortality. Therefore, it is necessary to develop a better understanding of the pathogenesis of this disease.
UI - 11872995
AU - Powles T; Imami N; Nelson M; Gazzard BG; Bower M
TI - Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
SO - AIDS 2002 Mar 8;16(4):531-6
AD - Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
OBJECTIVE: To measure the effects of combined chemotherapy and highly active antiretroviral therapy (HAART) on immune cell counts and plasma HIV-1 RNA loads in patients with AIDS-related lymphoma (ARL) to determine the implications for opportunistic infection prophylaxis and medium-term immune function. DESIGN AND METHODS: Peripheral blood total lymphocyte count, CD4 T-cell count, CD8 T-cell count, CD19 B-cell count, CD16/CD56 natural killer cell count and plasma HIV-1 RNA load were prospectively measured at ARL diagnosis, at 1 and 3 months during and 1, 3 and 6 months after chemotherapy in twenty patients receiving HAART. RESULTS: Significant declines in T-helper cell (CD4) count, natural killer cell (CD16/CD56) and B lymphocyte count (CD19 cells) occurred during the first 3 months of chemotherapy. There was no significant alteration in the T-cytotoxic cell (CD8) count, CD4 percentage or HIV-1 RNA load during the study period. The T-helper cell and natural killer cell counts recovered to pre-treatment levels within 1 month of finishing chemotherapy. The recovery of B-cells was slower with pre-treatment levels only being achieved after 3 months. The recovery of CD4 T-cell count following completion of chemotherapy was more rapid than described for ARL patients who were not receiving concomitant HAART. CONCLUSIONS: By combining chemotherapy with HAART, immune function is better maintained in the medium term. The CD4 T-cell count falls by 50% during chemotherapy and this will help to identify patients who require opportunistic infection prophylaxis during chemotherapy.
UI - 11920242
AU - Boulanger E; Agbalika F; Maarek O; Daniel MT; Grollet L; Molina JM;
TI - Sigaux F; Oksenhendler E A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
SO - Hematol J 2001;2(3):172-9
AD - Department of Clinical Immunohematology, Hopital Saint-Louis, Paris, France.
INTRODUCTION: Primary effusion lymphoma is a rare type of B-cell lymphoproliferative disorder which is mainly observed in patients with HIV infection. Lymphomatous cells bridge features of immunoblastic and anaplastic cells with a non-B non-T phenotype and are characterized by the presence of the human herpesvirus 8 genome. We report on the retrospective analysis of 12 cases. PATIENTS AND METHODS:: Twelve HIV-infected patients with serous effusions containing large HHV8(+) lymphomatous cells were extensively evaluated to disclose associated visceral involvement. Clonality was assessed by IgH gene rearrangement PCR analysis (n = 11) or Southern blot (n = 1). EBV and HHV8 DNA sequences were detected by PCR analysis. Cytogenetics studies were performed in seven cases using RHG-banding. RESULTS: Extraserous localizations of lymphoma were present in six cases (50%): mediastinal (n = 2), mesenteric (n = 2), pancreatic (n = 1), and bone marrow involvement (n = 1). A monoclonal rearrangement of IgH genes was demonstrated in six cases, an oligoclonal pattern in one, whereas no clonality could be detected in five. High HHV8 copy numbers were demonstrated in all effusion fluids, with EBV-co-infection in all cases but one. Cytogenetic analysis displayed a complex karyotype in all cases without recurrent abnormalities. Eight patients have died. Three patients are in complete remission at 28, 53 and 55 months after high-dose chemotherapy (n = 1), cidofovir and alpha-interferon combination therapy (n = 1), and antiretroviral therapy alone (n = 1). CONCLUSION: The clinical and molecular pattern, as well as the response to therapy suggest that primary effusion lymphoma represents an heterogenous type of virus-induced B-cell lymphoproliferative disorder, sharing pathophysiological features with that induced by the Epstein-Barr virus and occurring in immunocompromised patients.
UI - 11836577
AU - Silvestris N; Crucitta E; Lorusso V; Gamucci T; De Lena M
TI - AIDS-related non-Hodgkin's lymphoma: clinico-pathological characteristics and therapeutic strategies (review).
SO - Int J Oncol 2002 Mar;20(3):611-5
AD - Operative Unit of Medical Oncology, ASL of Frosinone, Bari, Italy.
High-grade B-cell non-Hodgkin's lymphoma (NHL), a diagnostic disease for the acquired immunodeficiency syndrome (AIDS), is a late manifestation of HIV infection and is generally related to severe lymphopenia. We reviewed the main clinico-pathological features of this disease and analysed its pathogenetic mechanisms with potential therapeutic implications.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.